Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy

Abstract

We report the occurrence of an acute encephalopathy following ifosfamide infusion, that we believe directly triggered by aprepitant (Emend™, Merck & Co., Inc.). Aprepitant, the first neurokinin-1 receptor antagonist, is a new antiemetic indicated for highly and moderately emetogenic chemotherapy, in association with 5-HT3 receptor antagonists and corticosteroids.